Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
Market Cap
6.815T
Market Weight
11.18%
Industries
11
Companies
1197
Healthcare S&P 500 ^GSPC
Loading Chart for Healthcare
DELL

Day Return

Sector
0.29%
S&P 500
0.51%

YTD Return

Sector
7.67%
S&P 500
13.20%

1-Year Return

Sector
7.08%
S&P 500
18.54%

3-Year Return

Sector
2.22%
S&P 500
22.38%

5-Year Return

Sector
66.74%
S&P 500
78.44%

Note: Sector performance is calculated based on the previous closing price of all sector constituents

Industries in This Sector

Select an Industry for a Visual Breakdown

IndustryMarket WeightYTD Return
All Industries
100.00%
7.67%
Drug Manufacturers - General
34.34%
14.51%
Healthcare Plans
13.42%
0.71%
Biotechnology
12.20%
7.02%
Medical Devices
11.69%
-0.96%
Diagnostics & Research
11.28%
6.33%
Medical Instruments & Supplies
6.60%
7.27%
Medical Care Facilities
3.17%
25.83%
Drug Manufacturers - Specialty & Generic
2.76%
-0.71%
Medical Distribution
2.33%
11.98%
Health Information Services
2.06%
9.26%
Pharmaceutical Retailers
0.15%
-55.25%

Note: Percentage % data on heatmap indicates Day Return

Largest Companies in This Sector

View More
Name
Last Price
1Y Target Est.
Market Weight
Market Cap
Day Change %
YTD Return
Avg. Analyst Rating
821.19 825.82 11.42% 774.241B -4.50% +40.88%
Buy
559.68 567.78 7.60% 515.185B -0.01% +6.31%
Buy
159.64 158.03 5.67% 384.202B +2.15% +1.85%
Buy
182.17 171.49 4.75% 321.689B +3.38% +17.55%
Buy
125.85 132.05 4.71% 318.932B -0.06% +15.44%
Buy
594.50 628.71 3.35% 226.93B +3.44% +12.00%
Buy
270.09 260.90 2.88% 195.063B +1.63% +16.75%
Buy
105.96 114.49 2.75% 186.593B -1.21% -3.73%
Buy
334.30 295.13 2.65% 179.33B -0.39% +16.07%
Buy
30.18 29.24 2.52% 171.018B +0.67% +4.83%
Hold

Investing in the Healthcare Sector

Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds

ETF Opportunities

View More
Name
Last Price
Net Assets
Expense Ratio
YTD Return
149.12 39.084B 0.09% +9.34%
273.55 20.601B 0.10% +9.11%
147.03 7.363B 0.45% +8.23%
100.98 7.126B 0.35% +13.09%
55.20 5.134B 0.40% +2.28%

Mutual Fund Opportunities

View More
Name
Last Price
Net Assets
Expense Ratio
YTD Return
224.78 47.799B 0.30% +7.49%
94.79 47.799B 0.30% +7.51%
136.92 20.601B 0.10% +9.17%
97.69 14.902B 0.80% +10.86%
97.38 14.902B 0.80% +10.78%

Healthcare Research

View More

Discover the Latest Analyst and Technical Research for This Sector

  • Analyst Report: Edwards Lifesciences Corporation

    Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US

    Rating
    Price Target
     
  • Analyst Report: West Pharmaceutical Services, Inc.

    West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

    Rating
    Price Target
     
  • Analyst Report: Thermo Fisher Scientific Inc.

    Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

    Rating
    Price Target
     
  • Analyst Report: Bausch + Lomb Corporation

    Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

    Rating
    Price Target
     

From the Community

Healthcare News